Since human cancer cells often display abnormal regulation of these cellular processes, the realization that PI3K signaling is disrupted at multiple levels has prompted researchers to develop targeted therapies against individual enzymes involved in this signaling cascade [3-6]. This evidence concerns the gene PIK3CA and cancer.